Connect with us

Medical Research

New Zynebra CBD Study Researches Sociobehavioral Symptom Management Effectiveness

Published

on

New Zynebra CBD Study Researches Sociobehavioral Symptom Management Effectiveness

Zynebra Pharmaceuticals Inc. released data this week at a symposium by the Society for the Study of Behavioral Phenotypes (SSBP). The data concerns CBD and its effectiveness in the management of socio-behavioral symptoms. The symptoms were linked to three neuropsychiatric disorders.

The company said in a statement,

“Data indicates that patients with autism spectrum disorder, Fragile X Syndrome and 22q11.2 Deletion Syndrome, share a constellation of sociobehavioral symptoms and that the pharmacology of CBD is broad, continues to be defined, and may prove to be beneficial in addressing important behavioral symptoms of these conditions.”

The company also indicated that the data suggests that those with the three neuropsychiatric disorders have shared sociobehavioral symptoms such as anxiety, which can cause “social avoidant behavior, aggression, irritability, low attention and poor communication.”

Dr. Honey Heussler, an associate professor at the University of Queensland, Australia, also stated

“Those of us who care for patients and families contending with certain neuropsychiatric dysfunction understand that there are significant shared sociobehavioral symptoms between such disorders, though until now no review has been conducted to examine or clarify the overlap. These data on the shared behaviors between ASD, FXS and 22qDS are important to understanding disease impact, patient care, and the development of potential treatments. One such potential treatment being studied in well-controlled clinical trials is a proprietary gel formulation of CBD, which has diverse pharmacologic effects and may prove to be important in these neuropsychiatric disorders.”

This is ultimately very little data and there is still very little evidence showing that CBD may be able to manage socio-behavioral symptoms and more research is needed.

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.